Strides Pharma Science Ltd · NSE:STAR
Strides Pharma Science — Q1 FY2022 Earnings Presentation
15 slides from Strides Pharma Science's earnings presentation, Aug 6, 2021
Slide 1: Q1FY22 Earnings
Q1FY22 Earnings August 6, 2021
Slide 2: Strides reports weak Q1FY22 results
Strides reports weak Q1FY22 results Revenues Q1FY22 has been a unprecedented quarter for Strides amidst multiple macro headwinds from the recent wave of Covid-19. This has led to significant disruptions both on the demand and supply side. The above headwinds have resulted in the company reporting an
Slide 3: Industry headwinds impacts performance across markets in Q1FY22
Industry headwinds impacts performance across markets in Q1FY22 Sector Headwinds Implications for Strides Mitigation Strategies US Business o Major headwinds faced by the sector o Witnessed double digit price erosion in our o Strides announced acquisition of basket of ANDAs and manufacturing site at
Slide 4: Financial performance in Q1FY22
Financial performance in Q1FY22 Q1FY22 Q4FY21 Q1FY21 QoQ% YoY% Revenues ₹6,919m ₹9,115m ₹7,847m - 24% -12% Gross Margins ₹3,428m ₹5,400m ₹4,825m - 37% - 29% 49.5% 61.5% 59.2% 61.5% - 970bps -1,200 bps EBITDA - ₹468m ₹1,602m ₹1,578m -129% -130% -6.8% 20.1% 17.6% 20.1% Adj PAT1 - ₹1,169m Adj EPS1 - ₹1
Slide 5: Performance Overview
Performance Overview Key Updates Regulated Markets Regulated Markets US Market Q1FY22 Q4FY21 Q1FY21 QoQ% YoY% • US revenues at $41m for Q1FY22 versus $50m in Q1FY21, US contributed 44% of consolidated revenues in Q1FY22 US1 3,016 4,273 3,738 -29% -19% • Markets witnessed significant drop in prescrip
Slide 6: Acquisition of ANDA portfolio from Endo solves for headwinds
Acquisition of ANDA portfolio from Endo solves for headwinds Portfolio more than doubles our current basket of 100 approved ANDA’s • Strides will pay ~US$24m for the acquisition of basket of ANDAs and the manufacturing facility at Chestnut Ridge, NY Transaction Details • The transaction will be fina
Slide 7: Acquisition of world class multi-dosage facility at Chestnut Ridge, New York
Acquisition of world class multi-dosage facility at Chestnut Ridge, New York 1 Built over an area of ~200,000 sq ft, the site adds new growth capacities of 2 billion units for the US markets Site expands our capabilities into niche domains including Hormones, Nasal Sprays, Gels, Modified Release pro
Slide 8: US business impacted by significant price erosion and drop in prescriptions
US business impacted by significant price erosion and drop in prescriptions Financial Performance (₹/$M) Business Updates Q U A R T E R O N Q U A R T E R Y E A R O N Y E A R • Revenues from the US for Q1FY22 stood at ₹3,016m ($41m), down 19% YoY, representing 44% of consolidated revenues for Q1FY22
Slide 9: Other regulated market reports a weak quarter, business to bounce back starting Q2FY22
Other regulated market reports a weak quarter, business to bounce back starting Q2FY22 Financial Performance (₹/$M) Business Updates Q U A R T E R O N Q U A R T E R Y E A R O N Y E A R • Revenues from other regulated markets for Q1FY22 stood at ₹2,232m ($30m), down 14% YoY, representing 32% of conso
Slide 10: Steady performance in emerging markets, Q1FY22 revenues up 1% YoY
Steady performance in emerging markets, Q1FY22 revenues up 11% YoY Financial Performance (₹/$M) Business Updates Q U A R T E R O N Q U A R T E R Y E A R O N Y E A R • Revenues from emerging markets for Q1FY22 stood at ₹1,671m ($23m), up 11% YoY, representing 24% of consolidated revenues for Q1FY22 •
Slide 11: Financial Performance
8 Strides Financial Performance
Slide 12: Net debt and Investments
Net debt and Investments Pharma Net Debt Investments in CHC & Biotech Total Net Debt As at March 2021 As at March 2021 As at March 2021 ₹ 5,948m ₹ 6,886m ₹ 12,834m As at June 2021 As at June 2021 As at June 2021 ₹ 7,530m ₹ 6,886m ₹ 14,416m Change over March 2021 Change over March 2021 Change over Ma
Slide 13: Key P&L Highlights – Q1FY22
Key P&L Highlights – Q1FY22 Income statement (₹m) Particulars Q1 FY22 Q4 FY21 Q1 FY21 QoQ YoY Revenues 6,919 9,115 7,847 -24% -12% EBITDA -468 1,602 1,578 -129% -130% EBITDA % -6.8% 17.6% 20.1% Adj PAT1 - 1,169 Adj EPS1 -13.0 Reconciliation of EBITDA (₹m) As per SEBI results Q1 FY22 Q4 FY21 Q1FY21 P
Slide 14: Q1FY22 Earnings Call, Friday, August 6, 2021
Strides Pharma Science Ltd – Q1FY22 Earnings Call Pre-register and join without operator Click here invites you to interact with the senior management on Q1FY22 Join through an operator using dial in numbers FRIDAY, AUGUST 6, 2021 India Primary +91 22 6280 1434 / +91 22 7115 8838 3:30pm IST / 11:00a
Slide 15: Thank you
Thank you Strides Pharma Science Limited CIN: L24230MH1990PLC057062 Regd. Office: 201, ‘Devavrata’, Sector - 17, Vashi, Navi Mumbai - 400 703 Corp. Office: Strides House, Bannerghatta Road, Bangalore – 560076 Investor Relations Sandeep Baid: sandeep.baid@strides.com
Strides Pharma Science — Q1 FY2022 Earnings Presentation on 6ix